



PreComb Therapeutics and the Eastern Switzerland University of Applied Sciences enter strategic collaboration

Hombrechtikon, Switzerland, July 9, 2021 - PreComb Therapeutics today announced the start of a strategic collaboration with Prof. Dr. Agathe Koller of the Institute of Lab Automation and Mechatronics (ILT) at the Eastern Switzerland University of Applied Sciences (OST). Together, the first fully automated point-of-care technology for functional precision medicine will be developed using 3-dimensional patient-derived microtumors.

"We are pleased to enter into this collaboration as part of a major Innosuisse project" said CEO Jens Kelm. "With ILT's long standing and profound experience in translating laboratory workflows into automated instruments, PreComb can significantly accelerate its development to provide R&D and clinical facilities with the first fully automated 3D microtumor testing device tailored for clinical relevance and predictive value. It is our shared vision to develop our technology towards the identification of the best possible therapy for every cancer patient, individually. "

The ILT brings extensive experience in automating and scaling up complex processes of the laboratory. "PreComb's technology will play a major role in personalized medicine by providing cancer patients with individually optimized therapies. We are proud to contribute to this exciting project and help bringing the very promising technology to the next level of automation" said Prof. Dr. Agathe Koller.

"We are very excited to collaborate with ILT-OST to further develop our proprietary 3D3 Technology for routine use of functional precision medicine in the clinic. Our novel technology will not only support physicians but also drug development companies in increasing the clinical relevance of drug screening to reduce development risks" said Olivier Mauti, CTO of PreComb.

About PreComb

PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring precision medicine benefits to all cancer patients. PreComb is pioneering breakthrough technologies to directly test the drug response of individual cancer patients, based on patient-derived 3D microtumors. For the first time, a fully automated point-of-care solution for determining drug sensitivity or resistance directly in the clinic is being developed. This offers the unique ability to routinely test entire portfolios of cancer drugs and drug combinations in large-scale, making the technology a universal tool from drug discovery to guiding therapies.

For more Information about PreComb Therapeutics, please visit www.precomb.com or follow us on [LinkedIn](#).

About ILT-OST

The ILT Institute for Lab Automation and Mechatronics is an institute of the OST – Eastern Switzerland University of Applied Sciences. The ILT provides expertise and applied research and development in the interdisciplinary field of automation and mechatronics. Its core competencies include laboratory automation, robotics, cyber-physical systems and medical engineering.

The ILT cooperates closely with industrial and academic partners in the field of innovation and technology transfer. The ILT supports its partners throughout the entire development process of mechatronic systems - from feasibility studies to pilot production.

For more Information about ILT, please visit www.ilt.hsr.ch or follow us on [LinkedIn](#).

PreComb Media contact

Dr. Jens M. Kelm

info@precomb.com

ILT Media contact

Prof. Dr. Agathe Koller

agathe.koller@ost.ch